Asfar Sohail Azmi

Oral PDE10 inhibitor ADT-030 curbed KRAS-mutant pancreatic cancer growth and metastasis in mouse models, stayed active in KRAS-inhibitor-resistant cells, and shifted tumor immune profiles.

This paper identifies a TGF-β/S100A9/CXCR2 axis in metastatic TNBC that drives neutrophil expansion and immune suppression, with S100A9 loss enhancing immunotherapy response.

This study shows that combining Menin and XPO1 inhibitors synergistically inhibits KMT2A-r and NPM1-m AML cell growth and improves survival in xenograft models.

This paper shows that combining Eltanexor and MRTX1133 improves efficacy in KRASG12D mutant PDAC by overcoming resistance and reducing tumor growth.

ADT-1004, a pan-RAS inhibitor, shows strong antitumor activity in pancreatic ductal adenocarcinoma models with high selectivity and tolerable dosing.

This study identifies RCC1 as a novel therapeutic target in PDAC, showing its role in tumor progression and drug resistance through the c-Myc-RCC1-Ran axis.